Vertex’ VP of Global R&D and CSO to retire


Peter Mueller joined the company in 2003

Biotechnology company Vertex Pharmaceuticals, based in Cambridge, MA, US, has announced that Peter Mueller, Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company.

Mueller’s retirement will be effective from 31 October, following a transition period. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.

Jeffrey Chodakewitz, Vertex’s Senior Vice President of Global Medicines Development and Medical Affairs and Chief Medical Officer, will continue to oversee all global clinical development programmes and other related functions and will assume additional responsibility for Regulatory Affairs and Global Patient Safety.

Sign up for your free email newsletter

Vertex expects to appoint a Head of Global Research to oversee its drug discovery efforts following Mueller’s retirement.